Anaptysbio (ANAB) EBIAT (2016 - 2025)
Anaptysbio's EBIAT history spans 10 years, with the latest figure at $49.6 million for Q4 2025.
- For Q4 2025, EBIAT rose 327.75% year-over-year to $49.6 million; the TTM value through Dec 2025 reached -$13.2 million, up 90.89%, while the annual FY2025 figure was -$13.2 million, 90.89% up from the prior year.
- EBIAT reached $49.6 million in Q4 2025 per ANAB's latest filing, up from $15.1 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $49.6 million in Q4 2025 to a low of -$46.7 million in Q2 2024.
- Average EBIAT over 5 years is -$25.4 million, with a median of -$33.2 million recorded in 2022.
- Peak YoY movement for EBIAT: crashed 7488.34% in 2022, then surged 327.75% in 2025.
- A 5-year view of EBIAT shows it stood at -$32.5 million in 2021, then increased by 18.82% to -$26.4 million in 2022, then crashed by 59.81% to -$42.2 million in 2023, then surged by 48.39% to -$21.8 million in 2024, then soared by 327.75% to $49.6 million in 2025.
- Per Business Quant, the three most recent readings for ANAB's EBIAT are $49.6 million (Q4 2025), $15.1 million (Q3 2025), and -$38.6 million (Q2 2025).